InvestorsHub Logo
Followers 4
Posts 1139
Boards Moderated 0
Alias Born 04/27/2006

Re: friendofthedevil post# 3905

Monday, 04/20/2015 6:46:11 PM

Monday, April 20, 2015 6:46:11 PM

Post# of 8555
I was wondering if this could have something to do with it. From this weekend from BMO posted on YMB by assted. Finally found it, could not remember and thought I was losing mind since could not find in PR.

" Dr. Sunil Hingorani discussed the targeting of hyaluronan (HA) in pancreatic cancer, noting that PEGPH20 combined with chemotherapy results in permanent favorable architectural changes after stoppage of PEGPH20.
Birchenough commented, "We maintain our Outperform rating on HALO following this weekend's AACR presentation and on prospects for PEGPH20 in pancreatic CA and other cancers with high HA expression. With impressive response rate and PFS data already established, we believe that enhanced biologic understanding of PEGPH20 action further increases confidence in prospects for success in pancreatic Ca. Durable benefit following early PEGPH20 termination and lasting effects on tumor vasculature could inform new dosing strategies to optimize therapeutic index across tumor types and realize the broad potential of PEGPH20 as a platform to enhance chemotherapy efficacy"


Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News